Esophageal Cancer clinical trials at UC Davis
7 research studies open to eligible people
A Study of Experimental NGM120 Combination Therapy for Advanced Solid Tumors and Pancreatic Cancer
open to eligible people ages 18 years and up
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.
Los Angeles, California and other locations
A Study of the Experimental Combination of Olaparib and Ramucirumab For Metastatic Gastric or Gastroesophageal Junction Cancer
open to eligible people ages 18 years and up
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab alone.
Sacramento, California and other locations
A Study of the Experimental Medicine INCB001158 Combined With Chemotherapy For Solid Tumor Cancers
open to eligible people ages 18 years and up
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
Sacramento, California and other locations
Experimental Cabozantinib With Pembrolizumab for Metastatic Gastric and Gastroesophageal Cancer
open to eligible people ages 18 years and up
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Orange, California
Experimental TAS-102 and Irinotecan for Gastric and Gastroesophageal Adenocarcinoma (stomach cancer)
open to eligible people ages 18 years and up
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Sacramento, California and other locations
Experimental Tislelizumab With Chemotherapy For Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Cancer
open to eligible people ages 18 years and up
This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line (1L) therapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Sacramento, California and other locations
Targeted therapy directed by genetic testing in treating patients with advanced solid tumors, lymphomas, or multiple myeloma
“Will identifying genetic abnormalities in tumor cells help doctors plan better, more personalized treatment for cancer patients?”
open to eligible people ages 18 years and up
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Sacramento, California and other locations
Last updated: